Cerebral edema and excitoxicity are well known phenomena and are reported in multiple pathological contexts. Despite 
Introduction
Traumatic brain injury (TBI) is a common clinical condition, one of the most frequent traumatic situations in the pediatric and adult ages, necessarily unforeseen and sudden in progress, with multiple causes (traffic accidents, falls, gunshot wounds) and possibly devastating consequences for the victim and a huge burden for the society, implying huge costs in public health care. Previous reports on humans 1,2 and animal models 3, 4 have shown, along with major neurological deficits/ symptoms (motor deficits, epilepsy), the persistence of unspecific complaints (namely headaches) and minor cognitive deficits -affected spatial orientation and memory, diminished learning abilities and work performance -directly related to neuronal hippocampal loss. 3, 5, 6 These symptoms, obvious after 48h, can persist over two weeks (postconcussion syndrome) and even become permanent. 7 It has also been associated with an increased risk for Depression 8 or neurodegenerative diseases. 9 Emotional processing disturbances can also be attributed to hippocampal damage, according to recent theories on cognitive/mnesic mechanisms and complex emotional states. 10 TBI is the cause of death in 30%-50% of all deaths related to traumatic events, 11, 12 with a mortality rate of 18,1/100.000 inhabitants (period 1995-2001), according to CDC (Centers for Disease Control, TBI Surveillance System) 13 (official sources). Even in low-energy trauma, representing 70% to 90% of all TBI's, 13 the risk for complications or progression of initial injury or cerebral edema poses a significant challenge for the neurosurgeon/neurointensivist. Despite the technology and medical care nowadays increasingly available, it is constantly reminded the need for further tools, capable of guiding the decision process and monitoring, and new therapeutic strategies, effective against self-sustained pathological processes.
Discussion
In TBI, one can distinguish the initial primary events of cellular damage and consequent neurological deficit, including intra-cranial bleeding or cerebral contusions as major primary lesions, and secondary mechanisms of loco-regional, cellular and biochemical deregulation -increased vascular permeability, vascular dilatation, ionic exchanges deregulation -leading to cerebral edema and cellular death (Figure 1 ). These secon dary pathological events, multifactorial in their nature, progress for days after the initial traumatic event and are theoretically subject to pharmacological intervention. It should be mentioned that, although most reports focus on neuronal damage, the concept of astrocyte and glial cell damage is gaining importance, as shown in recent reports, [14] [15] [16] [17] with parallel mechanisms of aggression. [18] [19] [20] Clinical and animal-model studies with microdialysis [21] [22] [23] [24] [25] and spectroscopy 27 (regarding pediatric ages) have shown a significant post-traumatic increase in extracellular levels of glutamate (Figure 2) , the main excitatory endogenous neurotransmitter of central nervous system, as well as of lactate (from anaerobic glicolysis) 27 and aspartate. 28 This was also shown in studies of cerebral spinal fluid from TBI victims. 29, 30 It should be mentioned that this increase is notorious as early as 6 hours after the trauma 27 but only reaches its peak only around 48h, 24 proving this is not a merely acute event. This increase, described in many hypoxicischemic situations in relation to apoptosis/necrosis 31 Glutamate and post-traumatic excitoxicity Alves JL, Pinto AM 35, 36 This pathological process leads to damage and cellular death, upon activation of ionotropic receptors NMDA or AMPA -type. More specifically, the activation of these receptors induces disruption of the homeostatic ionic balance, increasing intra-cellular levels of calcium ion (Ca2+), in relation, among other mechanisms, with the high sodium ion (Na+) concentration -revision by Floyd et al. 15 and others 37, 38 and inversion of the Na+-Ca2+ exchange system (sodiumcalcium exchanger, NCX). 39 In this way, innumerous enzymatic complexes are activated (phospholipases, endonucleases, proteases), leading to cytoskeleton damage. Other studies, using glutamate-sensitive astrocytic cell cultures 40 subject to mechanical trauma, have shown diminished intracellular Na+ levels and improved cellular survival upon glutamate transport inhibition by TBOA (DL-treo-beta-benziloxiaspartate). 15 This upset in Ca2+ metabolism, although acute, can last in time, as shown in studies proving delayed changes in Ca2+ homeostasis (30 days after the initial trauma), with rather unknown underlying mechanisms, in possible relation to clinical findings like post-traumatic seizures. 38 Adding to this, following initial cell injury, one can also observe mitochondrial damage and release of oxygen reactive species (ROS), promoting apoptosis, documented in TBI animal models from 2h to two weeks after the initial trauma. 41 The increase in ROS release in an ischemic event, as a starting point for oxidative stress, is apparently the result of high extracellular glutamate levels. 35, 42, 43 ROS are responsible for abnormal protein turnover, upsetting its normal function and interfering with cellular cycles, damaging DNA (breaks in chain or changes in the nucleotides components) (Figure 2) . Different studies addressing the use of antioxidant agents in ischemic events failed to show encouraging results. 43 Cell´s structural damage eventually will imply inversion of the normal function of glutamate receptors, on a neuronal and astrocytic level, in part due to ATP depletion as a result of iNOS-mediated (inducible nitric oxide synthase) 44, 45 nitric oxide release, with additional glutamate release to the extracellular compartment. 46, 47 Cellular damage, diminished glutamate uptake by sodium-dependent carriers, 39 augmented extracellular/synaptic levels of glutamate, they all contribute to increased cell injury or death, which will then result in reduced glutamate uptake and its increased spilling, promoting a self-sustained process of neuronal/ astrocytic aggression (Figure 2 ) (vicious circle) 18, 48, 49 , documented in several clinical contexts: TBI, medullary lesions, ischemic events, neurodegenerative diseases. 24, [50] [51] [52] These increasingly disseminated events, promoting secondary damage, are in part responsible for the pathological changes in structures topographically distant from the initial trauma (e.g. contra-lateral hippocampus), being a potential therapeutic target in an attempt to stop or attenuate the phenomena leading to secondary, possibly permanent, damage (Figure 3) . The pre-synaptic deregulation might itself be related to circuit alterations, 49 leading to behavioral changes and stimulus hypersensitivity, shown in animal models and humans victims of TBI.
Along with the frequent cortical contusion (or similar injury) and white matter tracts ultra-structural damage, 53 several experimental studies on TBI show significant damage to the ipsi and contra-lateral hippocampus, [54] [55] [56] including neuronal disruption on layer CA3 (up to 60% in the first 48h 55 and deafferentation in the CA1 layer. Immunohystochemical assays -GFAP and Fluor-Jade staining -confirm neuronal and astrocytic structural damage, namely in the layers previously mentioned -CA1 and CA3 -in the first 24h after TBI. 39 However, hippocampal damage is also observed in cell populations that, although not on necrosis/apoptosis processes, present several minor structural damages, including synaptic and dendritic degeneration, with diminished local synaptic density. 57 In animal models of repetitive minor TBI, disperse gliosis and minimal changes in the deeper layers were shown. 58 In several experimental models of posttraumatic hippocampal apoptotic phenomena, two distinct stages are obvious: an initial one -cellular damage and loss, followed by a progressive neuronal loss, persisting for days or even weeks 59, 60 ( Figure 3 ). Hippocampal neuronal loss, as well as lower threshold for excitability, is obvious bilaterally but only really persisting (30 days) on the same side of the impact. 61 Pyramidal CA3-layer and dentate gyrus hippocampal neurons appear to be most vulnerable to this bilateral degeneration 59 following unilateral trauma, as a result of systemic repercussion of an initially localized event.
The most frequent post-TBI cognitive impairment, memory disturbance, as well as spatial learning, can therefore be explained on anatomic-pathological grounds, regarding structural disruption, disturbance of neurometabolic equilibrium (documented in concussion-victims athletes submitted to MRI-spectroscopy 62 and interference with normal hippocampal synaptic transmission, 63, 64 including raised excitability potential 65 48h after TBI. Hippocampal damage is amplified, as expected, with low doses of keinate receptor agonists, glutamate analogues. 66 This can explain the neuroprotective effect, in animal models, of NMDA and AMPA-receptor antagonists 67 facing an initial hypoxic-ischemic aggression, 48 [68] [69] [70] Other therapeutic targets were tested in animal models, including neuropeptide Substance P, a modulator for Glutamate levels and NMDA receptors, using Neurokinin antagonists and cannabinoid receptors type 2 antagonists, with promising results regarding functional outcome. [71] [72] [73] [74] [75] The transition from animal experimental models to large prospective clinical trials has failed showing significant efficacy for these therapeutic agents, and none is included in the diverse daily-practice clinical protocols. Many reasons have been pointed for this: insufficient knowledge on pathophysiology, unknown optimal dosages and therapeutic timings, incorrect pharmacological preparation, arguable end-points, basic anatomical and physiological differences between human and animal models of disease, 76 among many others. 
Conclusion
With a multidisciplinary effort and profound knowledge of all the complex regulation systems involved, new specific therapies should be expected, capable of actively modulate the glutamatergic system and effectively play a role in diminishing morbidity and mortality in TBI.
